Scholar Rock Holding Corp Total Liabilities
Scholar Rock Holding Corp total liabilities. Based on the latest financial reports, Scholar Rock Holding Corp (SRRK) has total liabilities worth $166.72 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SRRK asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scholar Rock Holding Corp (2016–2024)
Total liabilities of Scholar Rock Holding Corp from 2016 to 2024. This chart illustrates how Scholar Rock Holding Corp's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Scholar Rock Holding Corp to see how much of total assets are deployed in long-term investments.
Scholar Rock Holding Corp Competitors by Total Liabilities
The table below lists competitors of Scholar Rock Holding Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amdocs Ltd
NASDAQ:DOX
|
USA | $2.88 Billion |
|
360 ONE WAM LIMITED
NSE:360ONE
|
India | Rs173.66 Billion |
|
Wix.Com Ltd
NASDAQ:WIX
|
USA | $2.98 Billion |
|
Balkrishna Industries Limited
NSE:BALKRISIND
|
India | Rs60.66 Billion |
|
United Plantations Bhd
KLSE:2089
|
Malaysia | RM548.41 Million |
|
TFS Financial Corporation
NASDAQ:TFSL
|
USA | $16.12 Billion |
|
Sotera Health Co
NASDAQ:SHC
|
USA | $2.64 Billion |
|
Hongta Securities Co Ltd
SHG:601236
|
China | CN¥40.29 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Scholar Rock Holding Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scholar Rock Holding Corp asset portfolio.
Liquidity & Leverage Metrics
Scholar Rock Holding Corp Total Liabilities Ratios Explained
Scholar Rock Holding Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scholar Rock Holding Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scholar Rock Holding Corp (2016–2024)
The table below shows the annual total liabilities of Scholar Rock Holding Corp from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $106.29 Million | +23.85% |
| 2023-12-31 | $85.82 Million | -12.37% |
| 2022-12-31 | $97.93 Million | -26.02% |
| 2021-12-31 | $132.37 Million | +3.79% |
| 2020-12-31 | $127.53 Million | +52.77% |
| 2019-12-31 | $83.48 Million | +11.73% |
| 2018-12-31 | $74.71 Million | -35.12% |
| 2017-12-31 | $115.16 Million | +83.35% |
| 2016-12-31 | $62.81 Million | -- |
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to deve… Read more